REGISTER
The clinical value of identifying resistance mechanisms
Prof. Curigliano and Prof. Meng discussed how liquid biopsy and molecular profiling can help guide subsequent therapeutic decision-making following resistance to CDK4/6 inhibitors.

Prof. Giuseppe Curigliano, European Institute of Oncology, Italy
Prof. Yanchun Meng, Fudan University Shanghai Cancer Center, China

Prof. Curigliano and Prof. Meng discussed how liquid biopsy and molecular profiling can help guide subsequent therapeutic decision-making following resistance to CDK4/6 inhibitors. They explored the clinical value of identifying resistance mechanisms, selecting subsequent targeted therapies, and refining treatment strategies based on molecular alterations detected after disease progression.

0
0
Loading